AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

UroGen Pharma to Present at March 2019 Investor Conferences

March 5, 2019

NEW YORK--(BUSINESS WIRE)--Mar 5, 2019--UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will present at two investor conferences in March:

  • Cowen and Company 39 th Annual Health Care Conference
    • Tuesday, March 12 th
    • 11:20AM Eastern Time
    • Boston, MA
  • Oppenheimer 29 th Annual Healthcare Conference
    • Tuesday, March 19 th
    • 9:10AM Eastern Time
    • New York, NY

A live audio webcast of each event will be available on the Investors section of UroGen’s website, www.urogen.com. A replay of each webcast will be available on the website for approximately two weeks.

About UroGen Pharma Ltd.

UroGen Pharma Ltd. (Nasdaq:URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. UroGen has developed RTGel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s lead investigational candidates, UGN-101 (mitomycin gel) for instillation, and UGN-102 (mitomycin gel) for intravesical instillation, are designed to potentially ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and bladder cancer, respectively. UroGen is headquartered in New York, NY with operations in Los Angeles, CA and Israel.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190305005221/en/

CONTACT: UROGEN:

Kate Bechtold

Director, Corporate Communications & Investor Relations

Kate.Bechtold@urogen.com

914-552-0456

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS NEW YORK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL RESEARCH SCIENCE GENERAL HEALTH

SOURCE: UroGen Pharma Ltd.

Copyright Business Wire 2019.

PUB: 03/05/2019 08:00 AM/DISC: 03/05/2019 08:01 AM

http://www.businesswire.com/news/home/20190305005221/en